WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Companies > Laboratorios Normon España
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Research
Orsini | December 04, 2020
Orsini Specialty Pharmacy, an innovator in uncommon illnesses and quality treatments, reported today that it has been chosen by Alnylam® Pharmaceuticals as a restricted appropriation accomplice for OXLUMO™ (lumasiran). OXLUMO is the solitary treatment affirmed for essential hyperoxaluria type 1 (PH1) to bring down urinary oxalate levels in pediatric and grown-up patients. PH1 is a super uncommon hereditary sickness described by the overproduction of oxalate, a side-effec...
Pharma Tech
ArisGlobal | August 23, 2022
ArisGlobal, the leading provider of life sciences software that automates core drug development functions with its end-to-end technology platform LifeSphere®, today recognizes and applauds the accomplishments of their LifeSphere® Regulatory IDMP product leader, Robin Schilling, for her acceptance into American National Standards Institute (ANSI) and the nonprofit's specific ISO Health Informatics Technical Committee, Working Group 6, which helps develop standardizations for Pharmacy ...
Innovation Pharmaceuticals, Fox Chase Chemical Diversity Center | July 23, 2020
Innovation Pharmaceuticals, a clinical stage biopharmaceutical company, announces today that the Company and Fox Chase Chemical Diversity Center, Inc. have amended an earlier collaborative research agreement related to antifungal drug discovery work. Under the amended terms, and in exchange for a six (6) percent fee tied to all potential future proceeds—including upfront payments, milestone payments and royalties—the Company is granting FCCDC all discovery, intellectua...
Pharmacy Market
Atara Biotherapeutics, Inc. | October 04, 2021
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) and Pierre Fabre today announced an exclusive commercialization agreement for tabelecleucel (tab-cel®) in Europe, Middle East, Africa, and other select emerging markets for Epstein-Barr virus (EBV)-positive cancers. Atara will retain full rights to tab-cel® in other major markets, including North America, Asia Pacific, and Latin America. Under the terms of the agreement, Atara will receive an upfront payment of USD 45 million, and...
Whitepaper
Business Insights, PHARMA TECH
Video
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE